electroCore, Inc. Announces Departure of JP Errico from the Board of Directors
News provided byelectroCore, Inc.
May 26, 2023, 4:01 PM ET
ROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the resignation of its Founder and former CEO, JP Errico from the Board of Directors. Mr. Errico will continue as a consultant and strategic advisor to the Company, focused on supporting the growth and direction of the wellness and human performance brands, Truvaga™ and TAC-STIM™.
“We are fortunate that electroCore will continue to benefit from Mr. Errico’s experience in the neuromodulation industry, his understanding of the physiology of the vagus nerve, and his knowledge of the markets and therapeutic mechanisms of our products, despite his absence from the Board room,” said Daniel Goldberger, Chief Executive Officer of electroCore. “He will continue to help advise the Company as it expands its commercial offerings through direct-to-consumer initiatives and maturing clinical programs.”
Mr. Peter Cuneo, Chairman of the Board of Directors, continued, “I would like to recognize and thank Mr. Errico for his past leadership and contributions to the Company during his tenure as a founder, member of management and the Board of Directors. His creativity and drive were imperative to the creation of non-invasive vagus nerve stimulation and his ongoing service to the Company will be valued.”
“I am pleased to take on a greater role as an advocate for science and education as the company explores non-invasive vagus nerve stimulation for optimizing neurodevelopment and cognitive function, preserving healthy metabolic function, and improving general wellbeing,” Mr. Errico said.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general well-being and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects or other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, Truvaga™, and TAC-STIM™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
NOTE: This content is not written by or endorsed by "KLFY", its advertisers, or Nexstar Media Inc.